Skip to main content
Premium Trial:

Request an Annual Quote

Genentech, Adaptimmune End Collaboration, License Agreement for T-Cell Receptor Therapies

NEW YORK – Genentech and Adaptimmune last week ended their collaboration and license agreement to codevelop two types of allogeneic T-cell therapies: off-the-shelf and personalized αβ T-cell therapies.

The termination of the agreement will become effective 180 days after the notice of termination last week. The two companies in 2021 began the collaboration, which was worth more than $3 billion in annual payments, milestone payments, and royalties. Under the terms of the agreement, Adaptimmune received $150 million in upfront payments and $35 million in milestone payments from Genentech, according to a filing with the US Securities and Exchange Commission. However, now that the companies are ending the collaboration, Adaptimmune will not receive any further milestone payments.

The two cell therapies the firms were focused on within this agreement were in the preclinical, discovery stage. Adaptimmune used its drug development platform to develop SPEAR T-cells, or Specific Peptide Enhanced Affinity Receptor T-cells, for the therapies.

Adaptimmune, based in Philadelphia, has several other T-cell therapies in its pipeline, including its lead candidate afamitresgene autoleucel, which is in late-stage development as a sarcoma treatment. The firm's other clinical programs include letetresgene autoleucel, which is under development for treating sarcoma and ovarian cancer, and uzatresgene autoleucel in head and neck and urothelial cancer.

"We've had a very valuable collaboration with our partner Genentech, and we continue to believe in the long-term potential of our iPSC-based allogeneic platform," Adaptimmune CEO Adrian Rawcliffe said in a statement. "Over the past 12 months, we've been resolutely focused on our late-stage autologous pipeline — in particular, our sarcoma franchise."

Rawcliffe added that the firm has the resources needed to bring afami-cel to market as planned. The US Food and Drug Administration is expected to decide whether to approve afami-cel's synovial sarcoma indication by Aug. 4.